Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals

Publisher: Bentham Science Publishers

E-ISSN: 1873-4286|15|9|983-987

ISSN: 1381-6128

Source: Current Pharmaceutical Design, Vol.15, Iss.9, 2009-03, pp. : 983-987

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Imaging of glucose metabolism has resulted in significant improvements in staging and follow-up in oncology. 18F-FDG PET has become a routine clinical test for most solid tumours. Several radionuclide-labeled derivatives of deoxyglucose that have shown that glucose metabolic imaging may be a useful tool for improving tumour staging, restaging, and monitoring of tumour response to therapy.